Study: "Profound" diagnoses of autism are far outnumbered by milder cases.

Published Date: 26 Apr 2023

Health officials have wondered how many U.S. children are being diagnosed with autism as it becomes more common. S. How many children experience more severe symptoms like a very low IQ and verbal immaturity, and how many kids have relatively mild symptoms?

Read Full News

Latest News

CAPN2-Targeting Agent AMX0114 Shows Safe Profile in Phase 1 LUMINA Trial of ALS Marco Meglio

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

NeurologyLive® Brain Games: December 21, 2025 Marco Meglio, Louie Pasculli

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!

Repositioning GLP-1 Drugs for Neurologic Disease: Evidence, Advances, and Outlook Marco Meglio

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

NeurologyLive® Friday 5 — December 19, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.

Frontlines with Frontera: Using Artificial Intelligence to Rethink Seizure Management in the Neuro ICU Jennifer Frontera, MD, Sahar Zafar, MD, MBBS

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]

FDA Expands Indication for n‐Butyl Cyanoacrylate in Chronic Subdural Hematoma Isabella Ciccone, MPH

The expanded indication brings n-butyl cyanoacrylate’s established performance into the treatment of chronic subdural hematoma, a condition for which traditional surgical interventions may not always be suitable or effective.

Todays Updates

This Week on NeurologyLive® — December 22, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis Marco Meglio

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease Marco Meglio

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia

Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia

COPD in 2025: Year in Review

COPD in 2025: Year in Review

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

Nephrology in 2025: Year in Review

Nephrology in 2025: Year in Review

Todays Updates

This Week on NeurologyLive® — December 22, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Remyelinating Agent PIPE-307 Falls Short in Phase 2 Trial of Relapsing Multiple Sclerosis Marco Meglio

Continuem's PIPE-307 trial for relapsing-remitting multiple sclerosis failed to meet primary goals, yet the company remains committed to exploring future therapies.

Brain-Penetrant Molecule GT-02287 Demonstrates Reversal of Glucosylsphinogosine in Parkinson Disease Marco Meglio

Gain Therapeutics advances Parkinson's treatment with GT 2287, showcasing promising safety and tolerability in ongoing trials. Discover the latest findings.

Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia

Daily Lemon Water Lowers Serum Urate Levels in Patients With Hyperuricemia

COPD in 2025: Year in Review

COPD in 2025: Year in Review

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

FDA Approves FUROSCIX On-Body Injector for Pediatric Patients, Accepts sNDA for ReadyFlow Autoinjector

Nephrology in 2025: Year in Review

Nephrology in 2025: Year in Review

Latest News

New findings from the LUMINA trial reveal AMX0114's safety in ALS patients, paving the way for further research and potential treatment advancements.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on neuromodulation for Parkinson disease!

GLP-1 research in neurology is on the rise, with several pivotal studies lending insights into their role.

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 19, 2025.

Frontlines with Frontera, a podcast hosted by neurointensivist Jennifer Frontera, MD, brings you an exclusive interview with Sahar Zafar, MD, MBBS. [LISTEN TIME: 30 minutes]

The expanded indication brings n-butyl cyanoacrylate’s established performance into the treatment of chronic subdural hematoma, a condition for which traditional surgical interventions may not always be suitable or effective.

News All Time

This Week on NeurologyLive® — December 15, 2025 Isabella Ciccone, MPH

Here's some of what is coming soon to NeurologyLive® this week.

Refining Prognosis and Treatment in Post–Resuscitation Epilepsy Care Andrea Rossetti, MD, Louie Pasculli

Andrea Rossetti, MD, director of the EEG/Epilepsy Unit at the Department of Clinical Neurosciences the Lausanne University Hospital in Switzerland, offers insight into post-resuscitation epilepsy care.

Beyond Dravet and LGS: Elizabeth Thiele, MD, PhD, on New Data for Epidiolex in DEEs Marco Meglio

Elizabeth Thiele, MD, PhD, director of the Pediatric Epilepsy Program at Massachusetts General Hospital, discusses new data on Epidiolex use in DEEs beyond Dravet, LGS, and TSC.

NeurologyLive® Friday 5 — December 12, 2025 Isabella Ciccone, MPH

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending December 12, 2025.

Investigational TRPM8 Antagonist Elismetrep Achieves Positive Phase 2b Data in Acute Migraine Isabella Ciccone, MPH

New data from a phase 2b trial showed that elismetrep showed favorable efficacy and safety outcomes compared with placebo, supporting its continued development as a potential acute migraine therapy.

Episode 156: Building Better Mood and Behavior Care for Parkinson Disease Marco Meglio, Sneha Mantri, MD, MS

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Sneha Mantri, MD, MS. [LISTEN TIME: 24 minutes]

FDA Approves Inebilizumab for AChR- and MuSK-Positive Generalized Myasthenia Gravis Isabella Ciccone, MPH

Inebilizumab is the first CD19-targeted B-cell therapy approved for antiAChR- or antiMuSK antibody–positive generalized myasthenia gravis, providing symptom control with twice-yearly dosing.

FDA Clears Pivotal Phase 3 PREVAiLS Study of Pridopidine in Early, Rapidly Progressive ALS Isabella Ciccone, MPH

The phase 3 study aims to confirm findings from the HEALEY ALS platform trial in patients with early-stage rapidly progressive ALS, which suggested potential benefits of pridopidine across multiple domains.

EPX-100 Shows Promising Seizure Reduction in Ongoing Open-Label Extension Louie Pasculli

New data from the open-label extension of Harmony Biosciences’ Phase 3 ARGUS trial show that EPX-100 (clemizole) achieved a median 50% reduction in countable motor seizures in patients with Dravet Syndrome.

Cell Therapy Deramiocel Meets Primary End Point in Phase 3 DMD Cardiomyopathy Trial Isabella Ciccone, MPH

Capricor Therapeutics anticipates that detailed phase 3 data from the HOPE-3 study will be submitted for presentation at a future scientific meeting and for publication in a peer-reviewed journal.

Michael Sperling, MD, on AES Lifetime Achievement Award, Evolution in Epilepsy Care Michael R. Sperling, MD, Louie Pasculli

Michael Sperling, MD, Baldwin Keyes Professor of Neurology at Vice Chair for Research at the Sidney Kimmel Medical College, spoke about the significance of receiving the Founders Award and the current state of epilepsy.

Z-Rostudirsen Meets Primary End Point in Phase 1/2 DELIVER Trial for Duchenne Muscular Dystrophy Isabella Ciccone, MPH

Long-term treatment with z-rostudirsen over 24 months showed sustained functional improvements across all end points in patients with Duchenne muscular dystrophy amenable to exon 51 skipping.

AES Poster Showcases Feasibility of Mobile App to Track Daily Self-Reporting Epilepsy Outcomes Isabella Ciccone, MPH

A new study presented at AES 2025 reported that a cognitive-behavioral intervention via mobile application for patients with epilepsy can reliably capture daily self-reported outcomes.

NeuroVoices: Richard Rammo, MD, on How Thalamic Neuromodulation is Evolving for Drug Resistant Epilepsy Marco Meglio, Richard Rammo, MD

The neurosurgeon at Cleveland Clinic discussed the goals of the AES thalamic neuromodulation special interest group and the major clinical and research priorities shaping the future of neuromodulation for drug resistant epilepsy.

FDA Accepts NDA for Low-Sodium Oxybate TRN-257 in Narcolepsy and Idiopathic Hypersomnia Isabella Ciccone, MPH

TRN-257, a treatment in development for adults with narcolepsy and idiopathic hypersomnia, is designed to reduce daily sodium exposure relative to existing higher-sodium therapies.

Survey identifies Fever-Related Seizure Reduction as Key Feature of CDKL5 Deficiency Disorder Louie Pasculli

A recent survey reveals fever significantly reduces seizure frequency in CDKL5 Deficiency Disorder, highlighting potential therapeutic strategies for patients.

Recommended News For You

Exercise can counter detrimental effects of cancer treatment, review suggests

Big Drop in Cervical Cancer Deaths; Publication Hijackers; A Win for CRC Home Tests

FDA Expands Approval of Osimertinib in Lung Cancer

Study finds 10% of pediatric blood cancers may stem from medical imaging radiation

Interleukin-6 may boost prediction of obesity-related cancers

Unified Neuro/Psych Residency Program: New Proposal.

Pickleball program boosts health and wellness for cancer survivors, study finds

Recommended Articles For You

The Statistical Horizon of Colorectal Cancer: From Global Trends to Precision Therapies and Colorectal Cancer 2025 Forecasts 

Unlocking the Benefits of Cyramza: A New Frontier in Cancer Treatment 

Management of Relapsed Synovial Sarcoma: Current Treatment Strategies and Emerging Therapies 

What Is A High MCV Level? Causes, Symptoms, And Treatment Options 

Whats more on Hidoc Dr.

Medical Updates
KOL Videos
Surveys
Events

Daily news to keep you up to date

Gain valuable insights with our in-depth KOL Video discussions

Participate and win cash vouchers

Get updates on the latest events happening around the world
Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Report suggests a big improvement in lung cancer survival

2.

Study reveals link between new-onset type 2 diabetes and some obesity-related cancers

3.

If CD19 CAR T-Cell Therapy Fails in Lymphoma, Try a CD22 Version

4.

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

5.

Research uncovers hidden Australian skin cancer epidemic

1.

The Latest Causes and Symptoms of Bowen's Disease: All You Need to Know 

2.

Breakthroughs in Oncology: Advances in Immunotherapy, Radiation & Precision Diagnostics

3.

A New Hope: Exploring the Potential of Pegaspargase in Treating Cancer

4.

Omitting Axillary Dissection in Node-Positive Breast Cancer: Insights from the SENOMAC Trial

5.

HIPEC in Platinum-Sensitive Ovarian Cancer: A Promising Yet Controversial Option

1.

International Lung Cancer Congress®

2.

Future NRG Oncology Meeting

3.

Genito-Urinary Oncology Summit 2026

4.

ISMB 2026 (Intelligent Systems for Molecular Biology)

5.

Annual International Congress on the Future of Breast Cancer East

1.

Cost Burden/ Burden of Hospitalization For R/R ALL Patients

2.

A Conclusive Discussion on CROWN Trial and the Dawn of a New Era in Frontline Management of ALK+ NSCLC

3.

Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV

4.

Navigating the Brain Barrier: The CNS Challenge in ALK+ NSCLC

5.

Iron Deficiency Anemia: Ferric Maltol As a New Treatment Option- Summarization of the New Perspective

Fastest Growing Medical Platform for Doctors

Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801

Phone :
+1-415-463-3094

Email :
anishagadia@hidoc.co

Quick Links

Drug DatabaseDrug InteractionDiseases Database
KOL VideosKnowledge HubQuizzes
Medical UpdatesEventsAbout Us

© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
Home
Profile
Login
bot